Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV p24 + MF59
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HIV p24 + MF59 is an experimental recombinant protein subunit vaccine candidate developed by Chiron Corporation for the prevention or treatment of HIV-1 infection. The vaccine consists of a recombinant version of the HIV-1 p24 capsid protein, which is a highly conserved internal protein of the virus, formulated with the MF59 adjuvant. MF59 is a squalene-based oil-in-water emulsion designed to enhance the magnitude and breadth of the immune response by recruiting and activating antigen-presenting cells at the injection site. Clinical evaluation, primarily in Phase I trials, focused on assessing the safety, tolerability, and immunogenicity of the vaccine in healthy, HIV-seronegative adults, specifically aiming to induce p24-specific humoral and cellular immune responses.
- Other names
- Chiron HIV p24/MF59 vaccinep24/MF59HIV p24 + MF59
02
Targets
gp120 C5 (HIV-1 gp120 C5 domain)p24 (HIV-1 capsid protein p24)
Beyond the preview
Go deeper on HIV p24 + MF59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV p24 + MF59.